Opportunity ID: 254474

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-FD-14-015
Funding Opportunity Title: Pharmacokinetic/Pharmacodynamic (PK/PD) Studies of Methylphenidate Extended Release Products in Attention Deficit Hyperactivity Disorder (ADHD) Patients (U01)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 1
Assistance Listings: 93.103 — Food and Drug Administration_Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Apr 29, 2014
Last Updated Date:
Original Closing Date for Applications: Jun 11, 2014
Current Closing Date for Applications: Jun 11, 2014
Archive Date: Jul 11, 2014
Estimated Total Program Funding: $1,000,000
Award Ceiling: $1,000,000
Award Floor: $950,000

Eligibility

Eligible Applicants: State governments
County governments
Private institutions of higher education
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
City or township governments
Native American tribal governments (Federally recognized)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Special district governments
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: FOREIGN INSTITUTIONS ARE ELIGIBLE TO APPLY

Additional Information

Agency Name: Food and Drug Administration
Description: The purpose of this project is to conduct a prospective PK/PD study in attention deficit hyperactivity disorder (ADHD) patients to link the PK profiles to the time-course of PD activity of methylphenidate extended release products in order to identify additional PK metrics (if any) that may impact the therapeutic equivalence of methylphenidate extended release products. The findings from the PK/PD study will help establish scientific and regulatory standards for assuring therapeutic equivalence of generic methylphenidate extended release products.
Link to Additional Information: FULL ANNOUNCEMENT
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Martin Bernard

Grants Management Specialist

Phone 240-402-7564
Email:Martin.Bernard@fda.hhs.gov

Version History

Version Modification Description Updated Date

Folder 254474 Full Announcement-1 -> sf424_rr_guide_general_adobe_verc1.pdf

Folder 254474 Full Announcement-1 -> rfa-fd-14-015_ pharmacokinetic_pharmacodynamic (pk_pd) studies of methylphen.pdf

Packages

Agency Contact Information: Martin Bernard
Grants Management Specialist
Phone 240-402-7564
Email: Martin.Bernard@fda.hhs.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
93.103 ADOBE-FORMS-C RFA-FD-14-015 PKG00195888 Apr 29, 2014 Jun 11, 2014 View

Package 1

Mandatory forms

254474 RR_SF424_2_0-2.0.pdf

254474 PHS398_ResearchPlan_2_0-2.0.pdf

254474 PHS398_CoverPageSupplement_2_0-2.0.pdf

254474 RR_Budget_1_3-1.3.pdf

254474 RR_KeyPersonExpanded_2_0-2.0.pdf

254474 RR_OtherProjectInfo_1_3-1.3.pdf

254474 PerformanceSite_2_0-2.0.pdf

Optional forms

254474 PlannedReport-1.0.pdf

254474 PHS398_CumulativeInclusionReport-1.0.pdf

254474 RR_SubawardBudget30_1_3-1.3.pdf

2025-07-09T11:42:52-05:00

Share This Post, Choose Your Platform!

About the Author: